- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03981575
Establecimiento de biomarcadores y criterios de valoración clínicos en la distrofia miotónica tipo 1 (END-DM1)
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogeneity going forward.
Funding Source- FDA OOPD
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Approximately 700 adult participants (18 to 70 years old, inclusive) with DM1 will be enrolled at 15 centers (up to 70 patients will be recruited at each site). No treatment will be administered as part of this study. Participants will receive standard of care as determined by the investigators. Study visits occur at baseline/0 months, 12 months, and 24 months. Few restrictions are placed on participation in the study because the investigators aim to capture the full spectrum of disease severity.
Muscle biopsy sub-study: Studies of splicing biomarkers in muscle biopsy samples will be conducted on a subset of 95 participants. These participants will have an additional study visit at 3 months.
Longitudinal muscle biopsy sub-study: Up to 30 individuals who have had a prior muscle biopsy as part of a DMCRN study will be asked to undergo another biopsy greater than 24 months after the prior biopsy. These participants will have an additional ad hoc biopsy visit.
COVID-19 sub-study: To evaluate severity of illness and response to COVID-19 vaccination in DM1 patients compared to corresponding data available about the general population, END-DM1 study participants will be asked to complete a one-time survey about COVID-19 experiences. A subset of those participants' blood samples will be analyzed to understand immunoglobulin response to infection and vaccination in DM1 patients.
Actigraphy sub-study: To assess daily physical activity in individuals with DM1 and evaluate physical activity changes over a 12-24 month period related to disease progression, a subset of participants will be asked to wear a small, wireless activity monitor while performing functional assessments described in the main study. Those participants will be asked to wear the activity monitor for 7 days following their research visit. Those participants will be asked to complete additional questionnaires.
Handheld Dynamometry sub-study: To evaluate additional muscle strength methods, a subset of participants will be asked to complete additional strength testing using either the MEDup or MicroFET handheld dynamometry device on the same day as their END-DM1 main study visit. Those participants will be asked to return to the clinic for a second visit within 10 days of the END-DM1 study visit to repeat the handheld dynamometry assessments and complete additional strength measures.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ruby Langeslay
- Número de teléfono: 804-828-8481
- Correo electrónico: ruby.langeslay@vcuhealth.org
Copia de seguridad de contactos de estudio
- Nombre: Jennifer Raymond
- Número de teléfono: 804-828-6318
- Correo electrónico: jennifer.raymond@vcuhealth.org
Ubicaciones de estudio
-
-
-
München, Alemania
- Reclutamiento
- Friedrich Baur Institute, Ludwig-Maximilians-Universität München
-
Contacto:
- Benedikt Schoser
- Número de teléfono: +49 (0)89 4400 57400
- Correo electrónico: benedikt.schoser@med.lmu.ede
-
Investigador principal:
- Benedikt Schoser, FEAN
-
Contacto:
- Corinna Wirner-Piotrowski
- Número de teléfono: +49 89 4400 57400
- Correo electrónico: Corinna.Wirner@med.uni-muenchen.de
-
-
-
-
-
Québec, Canadá
- Activo, no reclutando
- Université de Sherbrooke
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92703
- Reclutamiento
- University of California, San Diego
-
Investigador principal:
- Chamindra Laverty, MD
-
Contacto:
- Elizabeth Moreno
- Correo electrónico: e4moreno@health.ucsd.edu
-
Contacto:
- Gabriella Penner
- Correo electrónico: gpenner@health.ucsd.edu
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- University of California, Los Angeles
-
Investigador principal:
- Perry Shieh, MD, PhD
-
Contacto:
- Dennis Fernando
- Número de teléfono: 310-825-3264
- Correo electrónico: DeFernando@mednet.ucla.edu
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80204
- Reclutamiento
- University of Colorado - Denver
-
Contacto:
- Alyssa Avilez
- Número de teléfono: 303-724-4644
- Correo electrónico: alyssa.avilez@cuanschutz.edu
-
Contacto:
- Brianna Blume
- Número de teléfono: 303-724-6386
- Correo electrónico: brianna.blume@cuanschutz.edu
-
Investigador principal:
- Matthew Wicklund, MD
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32611
- Reclutamiento
- University of Florida
-
Investigador principal:
- Sankarsubramoney Subramony, MD
-
Contacto:
- Donovan Lott
- Correo electrónico: djlottpt@phhp.ufl.edu
-
Contacto:
- Whitney Miller
- Correo electrónico: whitney.miller@neurology.ufl.edu
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa
-
Investigador principal:
- Andrea Swenson, MD
-
Contacto:
- Maegan Tyrrell
- Número de teléfono: 319-356-8323
- Correo electrónico: maegan-tyrrell@uiowa.edu
-
Contacto:
- Loraine Brenner
- Correo electrónico: loraine-brenner@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Reclutamiento
- Kansas University Medical Center
-
Investigador principal:
- Jeffrey Statland, MD
-
Contacto:
- Michaela Walker
- Correo electrónico: mwalker20@kumc.edu
-
Contacto:
- Rebecca Clay
- Correo electrónico: rclay@kumc.edu
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Reclutamiento
- University of Rochester
-
Contacto:
- Jeanne Dekdebrun
- Número de teléfono: 585-276-4611
- Correo electrónico: Jeanne_dekdebrun@urmc.rochester.edu
-
Investigador principal:
- Johanna Hamel, MD
-
Contacto:
- Jim Hilbert
- Número de teléfono: 585-273-5590
- Correo electrónico: james_hilbert@urmc.rochester.edu
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- Ohio State University
-
Contacto:
- Kaneshia Hives
- Número de teléfono: 614-685-5661
- Correo electrónico: Kaneshia.Hives@osumc.edu
-
Contacto:
- Lischele Watkins
- Correo electrónico: lischele.watkins@osumc.edu
-
Investigador principal:
- Bakri Elsheikh, MD
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Houston Methodist Neurological Institute
-
Investigador principal:
- Erika P. Greene
-
Contacto:
- Kadeesia Brown
- Número de teléfono: 346-238-2295
- Correo electrónico: kbrown5@houstonmethodist.org
-
-
Virginia
-
Richmond, Virginia, Estados Unidos, 23298
- Reclutamiento
- Virginia Commonwealth University
-
Investigador principal:
- Nicholas Johnson, MD
-
Contacto:
- Jodie Howell
- Correo electrónico: jodie.howell@vcuhealth.org
-
Contacto:
- Carino Jennings
- Correo electrónico: Carino.Garza@vcuhealth.org
-
-
-
-
-
Milan, Italia
- Terminado
- Centro Clinico NeMO
-
-
-
-
-
Auckland, Nueva Zelanda
- Reclutamiento
- University of Auckland
-
Investigador principal:
- Richard Roxburgh
-
Contacto:
- Miriam Rodrigues
- Número de teléfono: 021896662
- Correo electrónico: mrodrigues@adhb.govt.nz
-
Contacto:
- Neerja Singh
- Correo electrónico: neerja.singh@auckland.ac.nz
-
-
-
-
-
Nijmegen, Países Bajos
- Reclutamiento
- Radboud University Medical Center
-
Contacto:
- Baziel vanEngelen
- Número de teléfono: (024) 366 8374
- Correo electrónico: Baziel.vanEngelen@radboudumc.nl
-
Investigador principal:
- Baziel van Engelen, MD
-
Contacto:
- Monique Plieger
- Correo electrónico: Monique.Plieger@radboudumc.nl
-
-
-
-
-
London, Reino Unido
- Reclutamiento
- University College London
-
Contacto:
- Chris Turner
- Correo electrónico: chris.turner7@nhs.net
-
Investigador principal:
- Chris Turner
-
Contacto:
- Iqraa Afzal
- Correo electrónico: iqraa.afzal@nhs.net
-
London, Reino Unido
- Reclutamiento
- St. George's, University of London
-
Contacto:
- Emma Matthews
- Número de teléfono: 020 8725 4162
- Correo electrónico: ematthew@sgul.ac.uk
-
Investigador principal:
- Emma Matthews
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
DM1 has a prevalence rate of approximately 1 per 2,300. There are no expected gender differences. Both men and women will be selected for this study.
Children with DM1 are not included in this project because the pathophysiological basis of congenital and childhood DM1 appears to be mechanistically distinct.
Descripción
Inclusion criteria:
- Age 18 to 70 (inclusive)
- Competent to provide informed consent
- Clinical diagnosis of DM1 based on research criteria1 or positive genetic test
- Comment: The clinical research criteria require myotonia, muscle weakness in a characteristic distribution, and history of similar findings in a first degree relative. Genetic testing confirmed the diagnosis of DM1 in > 99% of individuals who satisfied these criteria.2
Exclusion criteria:
- Symptomatic renal or liver disease, uncontrolled diabetes or thyroid disorder, or active malignancy other than skin cancer.
- Current alcohol or substance abuse
- Concurrent enrollment in clinical trial for DM1, or participation in trial within 6 months of entry.
- Concurrent pregnancy or planned pregnancy during the course of the study.
- Concurrent medical condition that would, in the opinion of the investigator or clinical evaluator, compromise performance on study measures.
- Note: non-ambulatory participants are not excluded, but are limited to <15% of enrollment.
Inclusion criteria for participants in the muscle biopsy sub-study:
• Of the 95 patients undergoing the tibialis anterior muscle biopsy, at least half will have at least moderate weakness of ankle dorsiflexion, defined as MRC score ≤ 4+. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy. Approximately 10 patients at each site will undergo the muscle biopsy.
Exclusion criteria for 95 participants in the muscle biopsy sub-study:
- Known CTG repeat expansion size less than 100 repeats, unless there are clear cut signs of limb weakness and muscle wasting. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy.
- Use of anticoagulant such as warfarin or a direct oral anticoagulant (e.g. dabigatran) due to the increased risk of bleeding.
- Use of aspirin or non-steroidal anti-inflammatory agents should be discontinued 3 days prior to the biopsy procedure, if possible.
- Platelet count <50,000 (if known) due to the increased risk of bleeding.
- History of a bleeding disorder due to the increased risk of bleeding.
- Advanced wasting of tibialis anterior (TA) muscle that precludes needle muscle biopsy in order to ensure that a sample taken would be of muscle and not just fat and fascia.
- Previous muscle biopsy of either TA in order to provide muscle tissue samples of non-biopsied muscles.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Study Visits
Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in ambulation over 24 months as measured by the 10 meter walk (m/s).
Periodo de tiempo: 12 and 24 months
|
10 meter walk will be measured (m/s) |
12 and 24 months
|
|
Change in respiratory function over 24 months as measured by spirometry, specifically the supine forced vital capacity (FVC).
Periodo de tiempo: 12 and 24 months
|
Supine forced vital capacity (% predicted) |
12 and 24 months
|
|
Percent splicing of DM1-affected splice events
Periodo de tiempo: 3 months
|
RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI) |
3 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Longitudinal Muscle Biopsy Sub-study: Characterization of RNA splicing measures over a prolonged period of time (>24 months)
Periodo de tiempo: 24 months
|
RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI) |
24 months
|
|
Longitudinal Muscle Biopsy Sub-study: Characterization of functional endpoints over a prolonged period of time (>24 months)
Periodo de tiempo: 24 months
|
10-meter walk/run, grip strength, ADF (ankle dorsiflexion) strength, supine FVC (forced vital capacity) |
24 months
|
|
COVID-19 Sub-study: Data from DM1 patients or caregivers about COVID-19 illness and vaccination experience, severity of illness and response to vaccination in DM1 patients compared to corresponding data available about the general population.
Periodo de tiempo: 24 months
|
To evaluate the severity and rate of COVID-19 infection in patients with DM1 compared to the general population symptomatic response to COVID-19 vaccination in DM1 patients |
24 months
|
|
COVID-19 Sub-study: Immunoglobulin profile and measles titers, and COVID-19 IgG titers
Periodo de tiempo: 24 months
|
To understand immunoglobulin response to infection and vaccination in DM1 patients |
24 months
|
|
Actigraphy Sub-study: Feasibility of measuring daily physical activity in individuals with DM1 in a multi-site study
Periodo de tiempo: 24 months
|
Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit to evaluate whether this type of activity monitoring is feasible in future trials. |
24 months
|
|
Actigraphy Sub-study: Objective daily physical activity using wireless accelerometry (ActiGraph), and comparison to normative values and patient reported physical activity.
Periodo de tiempo: 24 months
|
Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit and report physical activity, to establish physical activity data in the DM1 population. |
24 months
|
|
Actigraphy Sub-study: Physical activity changes over a 12-24 month period related to disease progression.
Periodo de tiempo: 24 months
|
Participants will wear the wireless activity monitor during the functional and strength measures, and complete additional study questionnaires at their regular END-DM1 study visits. |
24 months
|
|
Handheld Dynamometry Sub-study: Inter-rater reliability, standard error of measurement, and minimal detectable change of Maximal Isometric Muscle Strength force values obtained with the MEDup and MicroFET handheld dynamometers in adults with DM1
Periodo de tiempo: 24 months
|
Participants will be assessed using either the MEDup or MicroFET handheld dynamometer on the same day as an END-DM1 main study visit. Participants will complete a second visit +/- 10 days from that visit where HHD will be assessed using the same HHD method (either MEDup or MicroFET) used at the HHD visit. Additional functional and strength assessments will be captured at this visit. |
24 months
|
|
Handheld Dynamometry Sub-study: Comparison of quantitative muscle strength testing feasibility and validity between MEDup and MicroFET with the existing Fixed-QMT currently used in the END-DM1 study protocol.
Periodo de tiempo: 24 months
|
Data captured for MEDup and MicroFET will be compared to data collected using the Fixed-QMT measures in the main END-DM1 study. |
24 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Nicholas Johnson, MD, Virginia Commonwealth University
- Investigador principal: Charles Thornton, MD, University of Rochester
Publicaciones y enlaces útiles
Publicaciones Generales
- Leeuwenberg KE, Sansone VA, Hamel J, Hung M, Dekdebrun JM, Lizio A, Eichinger K, Gagnon C, Roxburgh RH, Subramony SH, Statland JM, Elsheikh BH, Turner C, Matthews EL, Ragole TE, Sampson JB, Schoser B, Takahashi MP, Wicklund MP, Swenson AJ, Laverty CG, Shieh PB, Greene EP, Raymond J, DeSpain E, Thornton CA, Mul K, Johnson NE; Myotonic Dystrophy Clinical Research Network. Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1. Neurology. 2026 Apr 14;106(7):e214747. doi: 10.1212/WNL.0000000000214747. Epub 2026 Feb 26.
- Mul K, Eichinger K, Hung M, Sansone VA, Gagnon C, Subramony S, Roxburgh RH, Hamel J, Statland JM, Elsheikh B, Turner C, Sampson J, Ragole T, Matthews E, Schoser B, Swenson A, Laverty C, Shieh P, Greene EP, Takahashi M, Wicklund M, Dekdebrun J, Raymond J, DeSpain E, Thornton CA, Johnson NE; Myotonic Dystrophy Clinical Research Network. Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study. PLoS One. 2025 Dec 11;20(12):e0331163. doi: 10.1371/journal.pone.0331163. eCollection 2025.
- Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman JM, Jones A, Butler A, Berggren KN, Dekdebrun J, Hung M, Lapato DM, Kiefer M, Thornton CA, Johnson NE, Hale MA; Myotonic Dystrophy Clinical Research Network (DMCRN). The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1. J Clin Invest. 2025 Jan 7;135(4):e185426. doi: 10.1172/JCI185426.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades del Sistema Nervioso
- Enfermedades Musculares
- Enfermedades Neuromusculares
- Enfermedades Genéticas Congénitas
- Enfermedades neurodegenerativas
- Trastornos Heredodegenerativos, Sistema Nervioso
- Trastornos Musculares Atróficos
- Distrofias Musculares
- Trastornos miotónicos
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Distrofia miotónica
Otros números de identificación del estudio
- HM20014419
- DMCRN (Otro identificador: University of Rochester)
- FD-R-006071 (Otro número de subvención/financiamiento: OPD)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Aggregated and deidentified data will be shared with qualified investigators upon majority approval of the DMCRN investigators.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .